Table 4.
Treatment characteristics of patients with invasive infection due to MRSA with vancomycin MICs of 2 μg/ml from 5 U.S. statesa
| Antibiotic and treatment history | n (%) | Median | Range |
|---|---|---|---|
| Vancomycin | 105 (82) | ||
| Length of in-hospital therapy (days) | 8 | 1–56 | |
| Linezolid | 12 (9) | ||
| Length of in-hospital therapy (days) | 8.5 | 2–49 | |
| Rifampin | 18 (14) | ||
| Length of in-hospital therapy (days) | 6 | 1–51 | |
| No. of patients discharged on therapy with antibiotic active against MRSA (n = 105)b | 67 (64) |
a
Data from the Active Bacterial Core Surveillance for Invasive MRSA Project (treatment information available for those hospitalized; n = 128).
b
A total of 23 patients died while in the hospital.